The role of oxidative stress in Parkinson's disease.
Vera Dias, Eunsung Junn, M Maral Mouradian
https://pubmed.ncbi.nlm.nih.gov/24252804Actively Recruiting
Phase 1
Age: 50Years - 80Years
All Genders
ID07064005
Brain Glutathione Enrichment Through Gamma-glutamylcysteine Supplementation in Early Parkinson's Disease Patients to Reduce Motor Disturbances and Cognitive Decline
Led by Pravat Mandal · Updated on 2026-05-04
12
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
Sponsors
P
Pravat Mandal
Lead Sponsor
W
Waste Connections Inc
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of oral Gamma-glutamylcysteine (GGC) supplementation in people with early Parkinson's Disease (PD). The study aims to measure changes in the brain and blood levels of glutathione, a key antioxidant, and how these changes relate to motor function, cognitive skills, and gut health in PD patients. This pilot trial focuses on understanding how GGC may influence disease progression through its antioxidant properties. Participants will take a 400 mg GGC tablet twice daily, once in the morning and once in the afternoon, for 12 months. Brain glutathione and iron levels will be measured using Magnetic Resonance Spectroscopy and Imaging before and after supplementation. Blood levels of glutathione and iron will also be tested at these times. Motor function and cognitive abilities will be assessed before and after the treatment period to monitor changes associated with GGC use. During the study, participants will undergo neuropsychological exams, motor function testing, and gut microbiome evaluations. Assessments include the Movement Disorders Society-Unified Parkinson's Disease Rating Scale and several cognitive tests such as the Repeatable Battery for the Assessment of Neuropsychological Status. Researchers will track glutathione and iron levels, motor and cognitive changes, and psychological distress over the 12-month period. This comprehensive monitoring will help evaluate the impact of GGC supplementation on PD symptoms and biological markers.
CONDITIONS
Brief Title
Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.
Who Can Participate
Age: 50Years - 80Years
All Genders
Eligibility Criteria
You may qualify if you...
- Confirmed Parkinson's Disease diagnosis
- Montreal Cognitive Assessment (MoCA) score of 26 or higher
- Age between 50 and 80 years
- Ability to read and write in English
You will not qualify if you...
- Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal fragments in the body
- Claustrophobia
- Diagnosis of Parkinson's disease dementia or dementia with Lewy bodies
- History of cancer
- Active psychosis or delirium
- Chronic kidney disease with creatinine over 1.5 mg/dL or liver disease with elevated AST or ALT within 30 days before enrollment
- Use of antioxidant therapies such as ashwagandha, gingko biloba, or N-acetylcysteine
- Illicit drug abuse or dependence
- Previous traumatic head injury
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Treatment
Duration - 12 months
Participants take Gamma-glutamylcysteine tablets 400 mg twice daily for brain glutathione enrichment.
Visits scheduled before and after 12 months of supplementation
Trial Site Locations
Total: 1 location
1
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
Loading map...
Research Team
P
Pravat K MANDAL, PHD
N
Nazia Pillar, M.S
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Glutathione Depletion and Concomitant Elevation of Susceptibility in Patients with Parkinson's Disease: State-of-the-Art MR Spectroscopy and Neuropsychological Study.
Deepika Shukla, Anshika Goel, Pravat K Mandal...
https://pubmed.ncbi.nlm.nih.gov/38050970Quantitation of Brain and Blood Glutathione and Iron in Healthy Age Groups Using Biophysical and In Vivo MR Spectroscopy: Potential Clinical Application.
Pravat K Mandal, Divya Dwivedi, Shallu Joon...
https://pubmed.ncbi.nlm.nih.gov/37257017